Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel maintenance after docetaxel in metastatic castration-resistant prostate cancer
2011-002965-39Phase 3Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) comparing Orteronel maintenance with Placebo maintenance (2 arms). Primary endpoint: Event-free survival. Started Mar 2013; status: terminated.
02
Drugs
orteronel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2011-002965-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002965-39.